290 related articles for article (PubMed ID: 27566561)
41. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
[TBL] [Abstract][Full Text] [Related]
42. Clinical validation of the PCR-reverse dot blot human papillomavirus genotyping test in cervical lesions from Chinese women in the Fujian province: a hospital-based population study.
Sun P; Song Y; Ruan G; Mao X; Kang Y; Dong B; Lin F
J Gynecol Oncol; 2017 Sep; 28(5):e50. PubMed ID: 28657218
[TBL] [Abstract][Full Text] [Related]
43. Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, ≥25 years of age, with NILM cytology.
Stoler MH; Wright TC; Parvu V; Yanson K; Cooper CK; Andrews J
Gynecol Oncol; 2019 Apr; 153(1):26-33. PubMed ID: 30638767
[TBL] [Abstract][Full Text] [Related]
44. [Results and cost evaluation of triage with high risk HPV test in cervical cancer screening. A pilot study in Piedmont (North-West Italy)].
Magnani C; Gillio Tos A; De Marco L; Calvia M; Cipelletti A; Bestagini P; Pagano E; Segnan N; Ronco G
Epidemiol Prev; 2012; 36(2):88-94. PubMed ID: 22706358
[TBL] [Abstract][Full Text] [Related]
45. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
[TBL] [Abstract][Full Text] [Related]
46. Three-year longitudinal data on the clinical performance of the Abbott RealTime High Risk HPV test in a cervical cancer screening setting.
Poljak M; Oštrbenk A; Seme K; Šterbenc A; Jančar N; Vrtačnik Bokal E
J Clin Virol; 2016 Mar; 76 Suppl 1():S29-S39. PubMed ID: 26643051
[TBL] [Abstract][Full Text] [Related]
47. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
[TBL] [Abstract][Full Text] [Related]
48. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
[TBL] [Abstract][Full Text] [Related]
49. The prevalence of VAIN, CIN, and related HPV genotypes in Japanese women with abnormal cytology.
Zhang S; Saito M; Yamada S; Sakamoto J; Takakura M; Takagi H; Sasagawa T
J Med Virol; 2020 Mar; 92(3):364-371. PubMed ID: 31642536
[TBL] [Abstract][Full Text] [Related]
50. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the performance of paired urine and cervical samples for cervical cancer screening in screening population.
Xu H; Yu Y; George W; Smith JS; Hu S; Dang L; Zhang X; Pan Q; Qiao Y; Zhao F
J Med Virol; 2020 Feb; 92(2):234-240. PubMed ID: 31535725
[TBL] [Abstract][Full Text] [Related]
52. Distribution of human papillomavirus infection: a population-based study of cervical samples from Jiangsu Province.
Zhang C; Cheng W; Liu Q; Guan Q; Zhang Q
Virol J; 2019 May; 16(1):67. PubMed ID: 31109361
[TBL] [Abstract][Full Text] [Related]
53. Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants.
Wang SS; Zuna RE; Wentzensen N; Dunn ST; Sherman ME; Gold MA; Schiffman M; Wacholder S; Allen RA; Block I; Downing K; Jeronimo J; Carreon JD; Safaeian M; Brown D; Walker JL
Cancer Epidemiol Biomarkers Prev; 2009 Jan; 18(1):113-20. PubMed ID: 19124488
[TBL] [Abstract][Full Text] [Related]
54. Pre-vaccination epidemiology of human papillomavirus infections in Japanese women with abnormal cytology.
Yamasaki K; Miura K; Shimada T; Ikemoto R; Miura S; Murakami M; Sameshima T; Fujishita A; Kotera K; Kinoshita A; Yoshiura K; Masuzaki H
J Obstet Gynaecol Res; 2011 Nov; 37(11):1666-70. PubMed ID: 21793993
[TBL] [Abstract][Full Text] [Related]
55. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
56. Prevalence and carcinogenic risk of high-risk human papillomavirus subtypes in different cervical cytology: a study of 124,251 cases from the largest academic center in China.
Tao X; Zhang H; Wang S; Chen T; Cong Q; Wang L; Zhou X; Zhao C
J Am Soc Cytopathol; 2021; 10(4):391-398. PubMed ID: 33906830
[TBL] [Abstract][Full Text] [Related]
57. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results.
Schiffman M; Burk RD; Boyle S; Raine-Bennett T; Katki HA; Gage JC; Wentzensen N; Kornegay JR; Aldrich C; Tam T; Erlich H; Apple R; Befano B; Castle PE
J Clin Microbiol; 2015 Jan; 53(1):52-9. PubMed ID: 25339396
[TBL] [Abstract][Full Text] [Related]
58. The prevalence, genotype distribution of human papillomavirus and cervical cytology in Wenzhou, China: a retrospective research of 7391 cases.
Lin Q; Lin X; Zhuang X; Tang Y; Zhao Z
Diagn Cytopathol; 2021 Feb; 49(2):211-218. PubMed ID: 32965784
[TBL] [Abstract][Full Text] [Related]
59. Clinical validation of Anyplex™ II HPV HR Detection according to the guidelines for HPV test requirements for cervical cancer screening.
Hesselink AT; Sahli R; Berkhof J; Snijders PJ; van der Salm ML; Agard D; Bleeker MC; Heideman DA
J Clin Virol; 2016 Mar; 76():36-9. PubMed ID: 26809131
[TBL] [Abstract][Full Text] [Related]
60. How to triage HPV positive cases: Results of four million females.
Gultekin M; Dundar S; Keskinkilic B; Turkyilmaz M; Ozgul N; Yuce K; Kara F
Gynecol Oncol; 2020 Jul; 158(1):105-111. PubMed ID: 32362567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
